http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2710227-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_baee372c55802742f9582e25c15ff11a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-542 |
| filingDate | 2015-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2748c616a1d4d0b7c93c006e74eb568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc031d13ecc70d4340a38dcd13679766 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_080a5bd2333727ffdf603baee396506e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be5f5d43cf1d6898c78b5e586576a24b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d123bc9b4d4564bbf27d447edf9d032d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec587a6e9f04df213435e9dc6a081cc9 |
| publicationDate | 2019-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2710227-C2 |
| titleOfInvention | Pharmaceutical composition based on condensed derivative of aminodihydrothiazine |
| abstract | FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to a pharmaceutical composition, namely a pharmaceutical composition for treating dementia and moderate cognitive disorders. Pharmaceutical composition for treating dementia and moderate cognitive disorders, containing a compound of formula (1):or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt thereof and a salt of a compound containing an aliphatic saturated C12-22 hydrocarbon group, where the salt of the compound containing an aliphatic saturated C12-22-hydrocarbon group is at least one salt selected from a group consisting of a salt of an aliphatic saturated organic C12-22-acid and metal, alkali metal mono-C12-22-alkyl fumarate monosalt and alkali-earth metal mono-C12-22-alkyl fumarate monosalt containing an aliphatic saturated C12-22-hydrocarbon group to total weight of the pharmaceutical composition from 0.1 wt. % to 10 wt. %.EFFECT: above described pharmaceutical composition enables to ensure no significant change in the dissolution profile, even after storage for a certain period of time.9 cl, 12 dwg, 15 tbl, 26 ex |
| priorityDate | 2014-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 107.